Quantcast

Latest Medical genetics Stories

2014-08-13 12:28:41

-- Analysis of over 17,000 cases finds that clinical performance of PanoramaTM NIPT is consistent in high and low risk populations -- SAN CARLOS, Calif., Aug. 13, 2014 /PRNewswire/ -- Natera, Inc., a leader in non-invasive genetic testing, today announced a study to be published in the November issue of American Journal of Obstetrics and Gynecology, which shows that Panorama(TM) NIPT performs consistently well in all pregnant women, regardless of their prior risk level. This is the largest...

2014-08-05 16:26:00

BETHESDA, Md., Aug. 5, 2014 /PRNewswire-USNewswire/ -- The American College of Medical Genetics and Genomics (ACMG) announced that the Thomson Reuters Impact Factor Journal Citation Reports has just increased the impact factor of the ACMG's peer-reviewed medical genetics and genomics journal, Genetics in Medicine (GIM) to 6.435 in 2013 up from 5.56 in 2012. GIM is currently ranked 17th of 164 titles in Genetics & Heredity category and in the very top echelon of genetic journals...

2014-07-31 12:29:39

Investment from Blue Cross Blue Shield of Massachusetts subsidiary will strengthen genetic benefits services ST. PETERSBURG, Fla., July 31, 2014 /PRNewswire-USNewswire/ -- InformedDNA, a leading provider of Genetic Benefits Management and the largest independent network of genetic specialists in the U.S., announced today that it has reached a $4.5 million funding agreement with Zaffre Investments, a wholly owned subsidiary of Blue Cross Blue Shield of Massachusetts. InformedDNA will...

2014-07-31 08:36:56

-- Panorama NIPT technology significantly reduces the number of false positives compared to quantitative NIPTs -- SAN CARLOS, Calif., July 31, 2014 /PRNewswire/ -- Natera, Inc., a leader in non-invasive genetic testing, today announced a study published in the August issue of Obstetrics and Gynecology, which demonstrates that the Panorama non-invasive prenatal test (NIPT) performs consistently well in all pregnant women, regardless of their prior risk level. This is the first major...

2014-07-22 08:32:03

- Neurotrope enters into world-wide, exclusive license agreement with Mount Sinai; Files related provisional patent for Bryostatin-1 - PLANTATION, Fla., July 22, 2014 /PRNewswire/ -- Neurotrope Bioscience, Inc., a subsidiary of Neurotrope, Inc. (OTCQB: NTRP) has signed a world-wide, exclusive license agreement with the Icahn School of Medicine at Mount Sinai (Mount Sinai) to utilize its proprietary information and data package for the use of Bryostatin-1 in the treatment of...

2014-07-10 12:31:08

Genetic Testing Service Designed to Detect Genetic Variants Linked to Autism Spectrum Disorders and Other Disorders of Childhood Development PROVO, Utah, July 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, the leader in genome annotation and interpretation, today announced an agreement with Lineagen, Inc., to provide next-generation sequencing (NGS) analytics for Lineagen's NextStep(Dx) PLUS. Lineagen, focused on the diagnostic evaluation of neurodevelopmental and neurological...

2014-07-10 08:29:24

Aims to provide evidence-based information to reduce misuse of genetic testing ST. PETERSBURG, Fla., July 10, 2014 /PRNewswire-USNewswire/ -- InformedDNA, the largest independent provider of genetic counseling services, released today a white paper that provides clarity on the appropriate use of genetic testing. Use of these diagnostic tests is growing rapidly, but inappropriate testing has negative consequences for individuals and the U.S. health care system. The paper, titled Genetic...

2014-07-07 16:24:11

NEW YORK, July 7, 2014 /PRNewswire/ -- Lysosomal storage disorders are a group of approximately 50 rare inherited metabolic disorders resulting from defects in lysosomal function. These severe, chronic genetic diseases have unmet medical needs, and include Fabry disease, Gaucher disease, Parkinson's disease, Pompe disease, and Tay-Sachs disease. The market for current drug therapies to address these disorders is estimated to exceed $3 billion. Amicus Therapeutics, Inc. (NASDAQ:...

2014-07-07 08:27:30

NextCODE capabilities will power ACoRD/UCD leadership in sequence-based diagnostics and large-scale whole-genome discovery efforts in pediatric disorders CAMBRIDGE, Mass., July 7, 2014 /PRNewswire/ -- NextCODE Health, which puts whole-genome analysis in the hands of clinicians and researchers worldwide, today announced the start of a partnership with the Academic Centre on Rare Diseases (ACoRD) at University College Dublin. ACoRD will use NextCODE solutions to take full advantage...

2014-07-07 04:20:59

COPENHAGEN, July 7, 2014 /PRNewswire/ -- BGI Diagnostics' NIFTY(TM) test becomes First NIPT based on Next Generation Sequencing Technology to be Approved by the China Food and Drug Administration (CFDA). On June 30, 2014, the CFDA approved the registration of BGI's BGISEQ-1000 and BGISEQ-100 sequencers, and its prenatal genetic testing kits for NIFTY(TM) (Non-Invasive Fetal Trisomy test). This is the first genetic test based on next generation sequencing technology to...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'